4.3 Letter

Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma

Journal

LEUKEMIA & LYMPHOMA
Volume 61, Issue 11, Pages 2767-2770

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2020.1783442

Keywords

-

Funding

  1. Amgen Inc.

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available